Renfu Pharmaceuticals: The drug registration certificate for icosapent ethyl soft capsules has been obtained.

Renfu Medicine announced that its wholly-owned subsidiary, Renfu Fuke Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of Twenty Carbon Five Ester Soft Capsules. This drug is used to reduce the levels of severe hypertriglyceridemia in adult patients on the basis of dietary control. It is used in conjunction with statins for the diagnosis of cardiovascular disease or diabetes with 2 other cardiovascular risk factors, combined with adult patients with high hypertriglyceridemia, to reduce the risk of cardiovascular events.